Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Kakegawa, K. Shimizu, M. Sugano, Yohei Miyamae, K. Kaira, T. Araki, T. Nakano, M. Kamiyoshihara, O. Kawashima, I. Takeyoshi (2011)
Clinicopathological features of lung adenocarcinoma with KRAS mutationsCancer, 117
J. Molina, S. Mandrekar, K. Rowland, N. Reuter, J. Jett, R. Marks, S. Schild, A. Adjei (2007)
D7-07: A phase II NCCTG “Window of Opportunity Front-line” study of the mTOR Inhibitor, CCI-779 (Temsirolimus) given as a single agent in patients with advanced NSCLCJournal of Thoracic Oncology, 2
Sae-Won Han, Tae-You Kim, P. Hwang, Soohyun Jeong, Jeong-Whun Kim, I. Choi, D. Oh, J. Kim, Dong-Wan Kim, D. Chung, S. Im, Y. Kim, J. Lee, D. Heo, Y. Bang, N. Kim (2005)
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 11
A. Marchetti, C. Martella, L. Felicioni, Fabio Barassi, S. Salvatore, A. Chella, P. Camplese, T. Iarussi, F. Mucilli, A. Mezzetti, F. Cuccurullo, R. Sacco, F. Buttitta (2005)
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 4
T. Kakkar, M. Ma, Zhuang Yao, Aaron Patton, Zheng Hu, B. Mounho (2007)
Pharmacokinetics and Safety of a Fully Human Hepatocyte Growth Factor Antibody, AMG 102, in Cynomolgus MonkeysPharmaceutical Research, 24
E. Kwak, Raffaella Sordella, D. Bell, N. Godin-Heymann, R. Okimoto, Brian Brannigan, Patricia Harris, David Driscoll, P. Fidias, T. Lynch, S. Rabindran, J. Mcginnis, A. Wissner, Sreenath Sharma, K. Isselbacher, J. Settleman, D. Haber (2005)
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.Proceedings of the National Academy of Sciences of the United States of America, 102 21
M. Bjornsti, P. Houghton (2004)
The tor pathway: a target for cancer therapyNature Reviews Cancer, 4
S. Rodenhuis, M. Wetering, W. Mooi, S. Evers, N. Zandwijk, J. Bos (1987)
Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung.The New England journal of medicine, 317 15
C. Gridelli, P. Maione, A. Rossi (2008)
The potential role of mTOR inhibitors in non-small cell lung cancer.The oncologist, 13 2
Donatella Malanga, M. Scrima, C. Marco, F. Fabiani, Nicla Rosa, Silvia Gisi, N. Malara, R. Savino, G. Rocco, G. Chiappetta, R. Franco, V. Tirino, G. Pirozzi, G. Viglietto (2008)
Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung.Cell cycle, 7 5
M. Tsao, A. Sakurada, J. Cutz, Chang-Qi Zhu, S. Kamel‐Reid, J. Squire, I. Lorimer, Tong Zhang, Ni Liu, M. Daneshmand, P. Marrano, G. Santos, A. Lagarde, F. Richardson, L. Seymour, M. Whitehead, K. Ding, J. Pater, F. Shepherd (2005)
Erlotinib in lung cancer - molecular and clinical predictors of outcome.The New England journal of medicine, 353 2
Andrew Tatem, Carlos Guerra, Peter Atkinson, Simon Hay (2004)
Athletics: Momentous sprint at the 2156 Olympics?Nature, 431
AT Skarin R Salgia (1998)
Molecular abnormalities in lung cancerJ Clin Oncol, 16
P. LoRusso, L. Appleman, A. Zhu, G. Shapiro, L. Fox, A. Wolanski, S. Hitchcock-bryan, L. Malburg, J. Eder (2006)
404 POSTER Pharmacodynamics (pd) of x1880, a novel spectrum selective kinase inhibitor (SSKI), administered orally to patients (pts) with advanced solid tumors (AST)Ejc Supplements, 4
V. Papadimitrakopoulou, A. Adjei (2006)
The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 1 7
M. Beau-Faller, A. Ruppert, Anna Voegeli, A. Neuville, Nicolas Meyer, E. Guérin, M. Legrain, B. Mennecier, J. Wihlm, G. Massard, E. Quoix, P. Oudet, M. Gaub (2008)
MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve CohortJournal of Thoracic Oncology, 3
A. Shaw, B. Yeap, M. Mino‐Kenudson, S. Digumarthy, D. Costa, R. Heist, B. Solomon, Hannah Stubbs, S. Admane, U. McDermott, J. Settleman, Susumu Kobayashi, E. Mark, S. Rodig, L. Chirieac, E. Kwak, T. Lynch, A. Iafrate (2009)
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 26
S. Aviel‐Ronen, F. Blackhall, F. Shepherd, M. Tsao (2006)
K-ras mutations in non-small-cell lung carcinoma: a review.Clinical lung cancer, 8 1
R. Herbst, A. Sandler (2008)
Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.The oncologist, 13 11
H. Shigematsu, Takao Takahashi, M. Nomura, Kuntal Majmudar, Makoto Suzuki, Hue Lee, I. Wistuba, K. Fong, S. Toyooka, N. Shimizu, T. Fujisawa, J. Minna, A. Gazdar (2005)
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.Cancer research, 65 5
Samanthi Perera, Danan Li, T. Shimamura, M. Raso, H. Ji, Liang Chen, Christa Borgman, Sara Zaghlul, K. Brandstetter, S. Kubo, Masaya Takahashi, L. Chirieac, R. Padera, R. Bronson, G. Shapiro, H. Greulich, M. Meyerson, U. Guertler, P. Chesa, F. Solca, I. Wistuba, Kwok-kin Wong (2009)
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapyProceedings of the National Academy of Sciences, 106
K. Naoki, Tzu-Hsiu Chen, W. Richards, D. Sugarbaker, M. Meyerson (2002)
Missense mutations of the BRAF gene in human lung adenocarcinoma.Cancer research, 62 23
Y. Choi, K. Takeuchi, M. Soda, K. Inamura, Yuki Togashi, S. Hatano, Munehiro Enomoto, T. Hamada, H. Haruta, Hideki Watanabe, K. Kurashina, Hisashi Hatanaka, Toshihide Ueno, S. Takada, Y. Yamashita, Y. Sugiyama, Y. Ishikawa, H. Mano (2008)
Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.Cancer research, 68 13
F. Cappuzzo, A. Marchetti, M. Skokan, E. Rossi, Sujatha Gajapathy, L. Felicioni, Maela Grammastro, M. Sciarrotta, F. Buttitta, M. Incarbone, L. Toschi, G. Finocchiaro, A. Destro, L. Terracciano, M. Roncalli, M. Alloisio, A. Santoro, M. Varella-Garcia (2009)
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 10
M. Fukuoka, Yi-long Wu, S. Thongprasert, P. Sunpaweravong, S. Leong, V. Sriuranpong, T. Chao, K. Nakagawa, D. Chu, N. Saijo, E. Duffield, Y. Rukazenkov, G. Speake, Haiyi Jiang, A. Armour, K. To, J. Yang, T. Mok (2011)
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 21
P. Reissmann, H. Koga, R. Figlin, E. Holmes, D. Slamon, The Group (1999)
Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancerJournal of Cancer Research and Clinical Oncology, 125
B. Balsara, J. Pei, Y. Mitsuuchi, R. Page, Andres Klein-Szanto, Hao Wang, M. Unger, J. Testa (2004)
Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions.Carcinogenesis, 25 11
T. Burgess, A. Coxon, S. Meyer, Jan Sun, K. Rex, T. Tsuruda, Qing Chen, Shu-Yin Ho, Luke Li, S. Kaufman, K. Mcdorman, R. Cattley, Jilin Sun, G. Elliott, Ke Zhang, Xiao Feng, X. Jia, L. Green, R. Radinsky, R. Kendall (2006)
Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.Cancer research, 66 3
Y. Choi, M. Soda, Y. Yamashita, Toshihide Ueno, Junpei Takashima, T. Nakajima, Y. Yatabe, K. Takeuchi, T. Hamada, H. Haruta, Y. Ishikawa, H. Kimura, T. Mitsudomi, Y. Tanio, H. Mano (2010)
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.The New England journal of medicine, 363 18
Y. Bang, Eunice Kwak, A. Shaw, D. Camidge, A. Iafrate, Robert Maki, Benjamin Solomon, Sai-Hong Ou, Ravi Salgia, Jeffrey Clark (2010)
Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 18_suppl
Donghui Li, Jeffrey Morris, Jun Liu, Manal Hassan, R. Day, Melissa Bondy, J. Abbruzzese (2009)
F1000 highlightsAsia‐Pacific Journal of Clinical Oncology, 5
K. Schmid, Natalie Oehl, F. Wrba, R. Pirker, C. Pirker, M. Filipits (2009)
EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node MetastasesClinical Cancer Research, 15
J. Grilley-Olson, D. Hayes, B. Qaqish, D. Moore, M. Socinski, X. Yin, M. Wilkerson, K. Leslie, W. Travis, W. Funkhouser (2016)
Diagnostic reproducibility of squamous cell carcinoma (SC) in the era of histology-directed non-small cell lung cancer (NSCLC) chemotherapy: A large prospective study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
T. Chou, C. Chiu, Ling-Hui Li, C. Hsiao, C. Tzen, Kuo‐Ting Chang, Yuh-Min Chen, R. Perng, S. Tsai, C. Tsai (2005)
Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung CancerClinical Cancer Research, 11
L. Ding, G. Getz, D. Wheeler, E. Mardis, M. McLellan, K. Cibulskis, C. Sougnez, H. Greulich, D. Muzny, M. Morgan, L. Fulton, R. Fulton, Qunyuan Zhang, M. Wendl, M. Lawrence, D. Larson, Ken Chen, D. Dooling, A. Sabo, A. Hawes, Hua Shen, S. Jhangiani, L. Lewis, O. Hall, Yiming Zhu, T. Mathew, Yanru Ren, Jiqiang Yao, S. Scherer, Kerstin Clerc, G. Metcalf, Brian Ng, A. Milosavljevic, M. Gonzalez-Garay, John Osborne, R. Meyer, Xiaoqi Shi, Yuzhu Tang, D. Koboldt, Ling Lin, R. Abbott, T. Miner, C. Pohl, G. Fewell, C. Haipek, Heather Schmidt, Brian Dunford-Shore, A. Kraja, S. Crosby, Christopher Sawyer, T. Vickery, Sacha Sander, J. Robinson, W. Winckler, J. Baldwin, L. Chirieac, A. Dutt, T. Fennell, M. Hanna, B. Johnson, R. Onofrio, Roman Thomas, G. Tonon, B. Weir, Xiaojun Zhao, L. Ziaugra, M. Zody, T. Giordano, M. Orringer, J. Roth, M. Spitz, I. Wistuba, B. Ozenberger, P. Good, A. Chang, D. Beer, M. Watson, M. Ladanyi, S. Broderick, A. Yoshizawa, W. Travis, W. Pao, M. Province, G. Weinstock, H. Varmus, S. Gabriel, E. Lander, R. Gibbs, M. Meyerson, R. Wilson (2008)
Somatic mutations affect key pathways in lung adenocarcinomaNature, 455
C. Mascaux, N. Iannino, B. Martin, M. Paesmans, T. Berghmans, Michèle Dusart, A. Haller, P. Lothaire, A. Meert, S. Noël, J. Lafitte, J. Sculier (2004)
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysisBritish Journal of Cancer, 92
F. Cappuzzo, L. Bemis, M. Varella-Garcia (2006)
HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.The New England journal of medicine, 354 24
R. Pirker, J. Pereira, A. Szczesna, J. Pawel, M. Krzakowski, R. Ramlau, I. Vynnychenko, Keunchil Park, Chih-Teng Yu, V. Ganul, J. Roh, E. Bajetta, K. O'Byrne, F. Marinis, W. Eberhardt, T. Goddemeier, M. Emig, U. Gatzemeier (2009)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialThe Lancet, 373
C. Gómez-Martín, B. Rubio-Viqueira, M. Hidalgo (2005)
Current status of mammalian target of rapamycin inhibitors in lung cancer.Clinical lung cancer, 7 Suppl 1
F. Hirsch, M. Varella-Garcia, P. Bunn, Michael Maria, R. Veve, Roy Bremmes, A. Baron, C. Zeng, W. Franklin (2003)
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 20
Y-L Wu TS Mok (2009)
Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinomaNew Eng J Med, 361
Gregory Riely, J. Marks, W. Pao (2009)
KRAS mutations in non-small cell lung cancer.Proceedings of the American Thoracic Society, 6 2
A Inoue M Maemondo (2010)
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med., 362
J. Koivunen, C. Mermel, K. Zejnullahu, C. Murphy, E. Lifshits, A. Holmes, H. Choi, Jhingook Kim, Derek Chiang, Roman Thomas, Jinseon Lee, W. Richards, D. Sugarbaker, C. Ducko, N. Lindeman, J. Marcoux, J. Engelman, N. Gray, Charles Lee, M. Meyerson, P. Jänne (2008)
EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerClinical Cancer Research, 14
M. Soda, Y. Choi, Munehiro Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, K. Kurashina, Hisashi Hatanaka, M. Bando, S. Ohno, Y. Ishikawa, H. Aburatani, T. Niki, Y. Sohara, Y. Sugiyama, H. Mano (2007)
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 448
A. Davies, D. Gandara, P. Lara, Z. Goldberg, P. Roberts, D. Lau (2002)
Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer.Seminars in oncology, 29 3 Suppl 12
Fredrick Barker, Fredrick Barker, Martha Simmons, Susan Chang, M. Prados, D. Larson, P. Sneed, W. Wara, Mitchell Berger, Pengchin Chen, Mark Israel, K. Aldape (2001)
EGFR overexpression and radiation response in glioblastoma multiforme.International journal of radiation oncology, biology, physics, 51 2
L. Horn, W. Pao (2009)
EML4-ALK: honing in on a new target in non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 26
T. Mitsudomi, S. Morita, Y. Yatabe, S. Negoro, I. Okamoto, J. Tsurutani, T. Seto, M. Satouchi, H. Tada, T. Hirashima, K. Asami, N. Katakami, M. Takada, H. Yoshioka, K. Shibata, S. Kudoh, E. Shimizu, H. Saito, S. Toyooka, K. Nakagawa, M. Fukuoka (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.The Lancet. Oncology, 11 2
H. Shigematsu, A. Gazdar (2006)
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancersInternational Journal of Cancer, 118
T. Mitsudomi, T. Kosaka, H. Endoh, Y. Horio, T. Hida, S. Mori, S. Hatooka, M. Shinoda, Takashi Takahashi, Y. Yatabe (2005)
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 11
C Hunter P Stephens (2004)
Lung cancer: intragenic ERBB2 kinase mutations in tumoursNature, 431
T. Kosaka, Y. Yatabe, H. Endoh, H. Kuwano, Takashi Takahashi, T. Mitsudomi (2004)
Mutations of the Epidermal Growth Factor Receptor Gene in Lung CancerCancer Research, 64
S. Cosimo, G. Ferretti, M. Milella, E. Martinelli, A. Alimonti, P. Papaldo, P. Carlini, A. Fabi, P. Matar, F. Cognetti (2004)
[Preclinical and clinical results with the epidermal growth factor receptor inhibitor Gefitinib (ZD1839, Iressa)].Minerva medica, 95 3
S. Shimizu, T. Mitsudomi (2002)
[Molecular abnormalities in lung cancer].Nihon rinsho. Japanese journal of clinical medicine, 60 Suppl 5
T. Mitsudomi, S. Steinberg, H. Oie, J. Mulshine, R. Phelps, J. Viallet, H. Pass, J. Minna, A. Gazdar (1991)
ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent.Cancer research, 51 18
Zuquan Zou, Xiao-Hong Zhang, Feng Wang, Qi-Jun Shen, Jin Xu, Li-Na Zhang, Wen-hua Xing, Ren-Jie Zhuo, Duo Li (2009)
A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.International journal of molecular medicine, 24 1
A. Sandler, R. Gray, M. Perry, J. Brahmer, J. Schiller, A. Dowlati, R. Lilenbaum, David Johnson (2006)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.The New England journal of medicine, 355 24
L. Howe, S. Leevers, N. Gómez, S. Nakielny, P. Cohen, C. Marshall (1992)
Activation of the MAP kinase pathway by the protein kinase rafCell, 71
Susumu Kobayashi, H. Ji, Y. Yuza, M. Meyerson, Kwok-kin Wong, D. Tenen, B. Halmos (2005)
An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.Cancer research, 65 16
Michael Boyer, F. Blackhall, Kyung-Ah Park, Carlos Barrios, M. Krzakowski, I. Taylor, Jane Liang, L. Denis, J. O'Connell, Suresh Ramalingam (2010)
Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 18_suppl
C. Yang, J. Shih, W. Su, T. Hsia, C. Tsai, S. Ou, R. Calvo, X. Cong, M. Shahidi, V. Miller (2010)
A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2).Journal of Clinical Oncology, 28
David Johnson, L. Fehrenbacher, W. Novotny, R. Herbst, J. Nemunaitis, D. Jablons, C. Langer, R. Devore, J. Gaudreault, L. Damico, E. Holmgren, F. Kabbinavar (2023)
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerJournal of Clinical Oncology, 41
Ryoichi Onozato, T. Kosaka, H. Kuwano, Y. Sekido, Y. Yatabe, T. Mitsudomi (2009)
Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung CancersJournal of Thoracic Oncology, 4
Hayes D Grilley-Olson JE (2009)
Diagnostic reproducibility of squamous cell carcinoma in the ear of the histology directed non-small cell chemotherapy: a large prospective study
(2009)
A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never smokers with advanced or metastatic adenocarcinoma of the lung
H. Sasaki, O. Kawano, K. Endo, E. Suzuki, H. Haneda, H. Yukiue, Y. Kobayashi, M. Yano, Y. Fujii (2006)
Uncommon V599E BRAF mutations in Japanese patients with lung cancer.The Journal of surgical research, 133 2
AA Adjei V Papadimitrakopoulou (2006)
The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapyJ Thorac Oncol, 1
J. Eder, G. Woude, S. Boerner, P. LoRusso (2009)
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in CancerClinical Cancer Research, 15
W. Pao, V. Miller, K. Politi, Gregory Riely, R. Somwar, M. Zakowski, M. Kris, H. Varmus (2005)
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLoS Medicine, 2
J. Engelman, K. Zejnullahu, T. Mitsudomi, Youngchul Song, Courtney Hyland, Joon-Oh Park, N. Lindeman, Christopher-Michael Gale, Xiaojun Zhao, J. Christensen, T. Kosaka, A. Holmes, A. Rogers, F. Cappuzzo, T. Mok, Charles Lee, B. Johnson, L. Cantley, P. Jänne (2007)
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 316
J. Bean, C. Brennan, J. Shih, Gregory Riely, A. Viale, Lu Wang, D. Chitale, N. Motoi, J. Szőke, S. Broderick, M. Balak, Wen‐Cheng Chang, Chong-Jen Yu, Adi Gazdar, H. Pass, V. Rusch, W. Gerald, Shiu-Feng Huang, Pan‐Chyr Yang, V. Miller, M. Ladanyi, Chih‐Hsin Yang, W. Pao (2007)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProceedings of the National Academy of Sciences, 104
Xiaotong Zhang, L-Y Li, X. Mu, Q. Cui, X.-Y. Chang, W. Song, S-L Wang, Mengzhao Wang, W. Zhong, Lanjun Zhang (2005)
The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 16 8
P. Jänne (2005)
Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations.Seminars in oncology, 32 6 Suppl 10
Gregory Riely, M. Kris, D. Rosenbaum, J. Marks, Allan Li, D. Chitale, K. Nafa, E. Riedel, M. Hsu, W. Pao, V. Miller, M. Ladanyi (2008)
Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung AdenocarcinomaClinical Cancer Research, 14
(2009)
Clinical activity of BIBW2992, an irreversible inhibitor of EGFR and HER2 in adenocarcinoma of the lung with mutations in the kinase domain of HER2neu
G. Scagliotti, S. Novello, J. Pawel, M. Reck, J. Pereira, Michael Thomas, José Miziara, B. Bálint, F. Marinis, A. Keller, O. Aren, Maria Csollak, I. Albert, C. Barrios, F. Grossi, M. Krzakowski, L. Cupit, F. Cihon, S. Dimatteo, N. Hanna (2010)
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 11
T. Mitsudomi (2009)
[Small-molecule tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR)].Gan to kagaku ryoho. Cancer & chemotherapy, 36 7
E. Kwak, Y. Bang, D. Camidge, A. Shaw, B. Solomon, Robert Maki, Sai-Hong Ou, Bruce Dezube, P. Jänne, Daniel, B. Costa, M. Varella-Garcia, W. Kim, Thomas Lynch, P. Fidias, Hannah Stubbs, J. Engelman, V. Lecia, Sequist, Weiwei Tan, L. Gandhi, M. Mino‐Kenudson, Greg Wei, S. Shreeve, M. Ratain, Jeffrey, Settleman, James Christensen, D. Haber, K. Wilner, R. Salgia, Geoffrey Shapiro, J. Clark, A. Iafrate (2010)
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.The New England journal of medicine, 363 18
S. Ahrendt, P. Decker, Enas Alawi, Yong‐ran Zhu, M. Sanchez-Cespedes, Stephen Yang, G. Haasler, A. Kajdacsy‐Balla, M. Demeure, D. Sidransky (2001)
Cigarette smoking is strongly associated with mutation of the K‐ras gene in patients with primary adenocarcinoma of the lungCancer, 92
L Fehrenbacher D Johnson (2004)
Randomised phase II trial comprising bevacizumab plus carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancerJ Clin Oncol, 22
DR Gandara A Davies (2002)
Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancerSemin Oncol, 29
Heather Nelson, D. Christiani, E. Mark, J. Wiencke, J. Wain, K. Kelsey (1999)
Implications and prognostic value of K-ras mutation for early-stage lung cancer in women.Journal of the National Cancer Institute, 91 23
S. Wang, A. Narasanna, Marianela Pérez-Torres, B. Xiang, Frederick Wu, Seungchan Yang, G. Carpenter, A. Gazdar, S. Muthuswamy, C. Arteaga (2006)
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.Cancer cell, 10 1
D. Bell, T. Lynch, Sara Haserlat, Patricia Harris, R. Okimoto, Brian Brannigan, D. Sgroi, B. Muir, M. Riemenschneider, R. Iacona, A. Krebs, David Johnson, G. Giaccone, R. Herbst, C. Manegold, M. Fukuoka, M. Kris, J. Baselga, J. Ochs, D. Haber (2005)
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 31
J. Schiller, W. Akerley, W. Brugger, D. Ferrari, E. Garmey, D. Gerber, S. Orlov, R. Ramlau, J. Pawel, L. Sequist (2010)
Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 18_suppl
Abstract Lung cancer remains the leading cause of cancer-related mortality in the world despite advances in the field of cancer therapeutics. Traditional treatment with empirically chosen cytotoxic chemotherapeutic agents, have given small, but real survival benefits. Recent advances and insights into molecular pathogenesis of lung cancers have provided some novel molecular targets, offering newer strategies and agents that are tumor specific. Studies have identified mutations in specific genes that are involved in driving the development of lung cancer and so it is important to subsequently target them with specific drugs thus changing paradigms of management of this type of cancer. Recently, Lung Cancer Mutation Consortium (LCMC) has identified at least one of the many recognized “driver mutations” in nearly two thirds of the patients with advanced cancer. This study suggests that identification of driver mutations can help in molecular targeted therapeutics and in addition supplant tumor histology in guiding treatment decisions, identifying subset of patients who may benefit therapy. This review focuses on these mutations identified in specific genes serving as “drivers” of lung tumorigenesis and suggests that clear promise for the future of lung cancer treatment is indeed personalized therapy with drugs chosen according to the patient mutation profile. Most clinically relevant translational advances made in genes involved in lung tumorigenesis namely EML4-ALK fusions, HER2, PIK3CA, AKT, BRAF, MAP2K1, MET mutations and amplifications along with the well established EGFR and KRAS mutations are discussed in the context of NSCLCs. These studies emphasize the need for treatment management based on mutation profile along with routine histology based classification of these tumors in future for a directed therapy and thus a better therapeutic outcome.
Indian Journal of Surgical Oncology – Springer Journals
Published: Sep 1, 2011
Keywords: surgical oncology; oncology; surgery
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.